New drugs: methylnaltrexone bromide, alvimopan, and rilonacept.
Hussar
Daniel A
DA
College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000701:Analgesics, Opioid / Q000009:adverse effects; D002352:Carrier Proteins / Q000235:genetics; D003248:Constipation / Q000139:chemically induced / Q000188:drug therapy; D010505:Familial Mediterranean Fever / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D045823:Ileus / Q000188:drug therapy / Q000209:etiology; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D009271:Naltrexone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009292:Narcotic Antagonists / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D013577:Syndrome
D000701:Analgesics, Opioid; D002352:Carrier Proteins; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human; D009292:Narcotic Antagonists; D010880:Piperidines; D000644:Quaternary Ammonium Compounds; D011993:Recombinant Fusion Proteins; C032257:methylnaltrexone; D009271:Naltrexone; C419502:alvimopan; C531377:rilonacept